Publications by authors named "Daniel W Lee"

Claim this Profile
T
Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-CD3×anti-GD2 bispecific antibody armed T cells.
Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Daniel W Lee

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome.
Haneen Shalabi, Cynthia Harrison, Bonnie Yates, Katherine R Calvo, Daniel W Lee

Pediatr Blood Cancer· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.
Maxim Yankelevich, Archana Thakur, Shakeel Modak, Roland Chu, Jeffrey Taub, Daniel W Lee

Res Sq· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials.
Sara K Silbert, Sanna Madan, Elizabeth M Holland, Seth M Steinberg, Lauren Little, Daniel W Lee

Blood Adv· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia.
Alan S Wayne, Van Huynh, Nobuko Hijiya, Rayne H Rouce, Patrick A Brown, Daniel W Lee

Haematologica· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preinfusion factors impacting relapse immunophenotype following CD19 CAR T cells.
Adam J Lamble, Regina M Myers, Agne Taraseviciute, Samuel John, Bonnie Yates, Lee Chen, Daniel W Lee, Colleen Annesley

Blood Adv· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes.
Aiman J Faruqi, John A Ligon, Paul Borgman, Seth M Steinberg, Toni Foley, Daniel W Lee

Blood Adv· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neurotoxicity following CD19/CD28ζ CAR T-cells in children and young adults with B-cell malignancies.
Haneen Shalabi, Staci Martin, Bonnie Yates, Pamela L Wolters, Claire Kaplan, Daniel W Lee

Neuro Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low rate of subsequent malignant neoplasms after CD19 CAR T-cell therapy.
Emily M Hsieh, Regina M Myers, Bonnie Yates, Colleen Annesley, Samuel John, Lee Chen, Daniel W Lee

Blood Adv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD19/22 CAR T cells in children and young adults with B-ALL: phase 1 results and development of a novel bicistronic CAR.
Haneen Shalabi, Haiying Qin, Angela Su, Bonnie Yates, Pamela L Wolters, Daniel W Lee

Blood· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of second CAR-T (CART2) infusion limited by poor CART expansion and antigen modulation.
Elizabeth M Holland, John C Molina, Kniya Dede, Daniel Moyer, Ting Zhou, Daniel W Lee

J Immunother Cancer· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy.
Elizabeth M Holland, Bonnie Yates, Alex Ling, Constance M Yuan, Hao-Wei Wang, Daniel W Lee

Blood Adv· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALL.
Regina M Myers, Agne Taraseviciute, Seth M Steinberg, Adam J Lamble, Jennifer Sheppard, Lee Chen, Daniel W Lee, Colleen Annesley

J Clin Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting of the alpha beta integrin complex by CAR-T cells leads to rapid regression of diffuse intrinsic pontine glioma and glioblastoma.
Dustin A Cobb, Jacopo de Rossi, Lixia Liu, Erin An, Daniel W Lee

J Immunother Cancer· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Factors Impacting Overall and Event-Free Survival following Post-Chimeric Antigen Receptor T Cell Consolidative Hematopoietic Stem Cell Transplantation.
John C Molina, Seth M Steinberg, Bonnie Yates, Daniel W Lee, Lauren Little

Transplant Cell Ther· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days.
Lekha Mikkilineni, Bonnie Yates, Seth M Steinberg, Shilpa A Shahani, John C Molina, Daniel W Lee

Blood Adv· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL.
Nirali N Shah, Daniel W Lee, Bonnie Yates, Constance M Yuan, Haneen Shalabi

J Clin Oncol· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cytokine Release Syndrome Biology and Management.
Dustin A Cobb, Daniel W Lee

Cancer J· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events.
Marcela V Maus, Sara Alexander, Michael R Bishop, Jennifer N Brudno, Colleen Callahan, Daniel W Lee

J Immunother Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with hematological malignancies.
Haneen Shalabi, Vandana Sachdev, Amita Kulshreshtha, Julia W Cohen, Bonnie Yates, Daniel W Lee

J Immunother Cancer· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of T-Cell Engaging Immunotherapy Complications.
Indumathy Varadarajan, Daniel W Lee

Cancer J· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease detection methodologies in relapsed B-cell acute lymphoblastic leukemia: Opportunities for improvement.
Haneen Shalabi, Constance M Yuan, Amita Kulshreshtha, Alina Dulau-Florea, Dalia Salem, Daniel W Lee

Pediatr Blood Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply.
Daniel W Lee, Elena Mead, Bianca D Santomasso, Cameron J Turtle, Stephan A Grupp

Biol Blood Marrow Transplant· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Robbie G Majzner, Johanna L Theruvath, Anandani Nellan, Sabine Heitzeneder, Yongzhi Cui, Daniel W Lee

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current approaches in the grading and management of cytokine release syndrome after chimeric antigen receptor T-cell therapy.
Lara L Riegler, Gavin P Jones, Daniel W Lee

Ther Clin Risk Manag· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis